- Idarubicin
- Idarubicin hydrochloride
- 58958-60-4Propanoic acid,2,2-dimethyl-, isooctadecyl ester
- 589-59-3Butanoic acid,3-methyl-, 2-methylpropyl ester
- 58960-71-7L-Tyrosine,3,5-dibromo-N-[(1,1-dimethylethoxy)carbonyl]-
- 5896-17-3Benzaldehyde,2-(phenylmethoxy)-
- 58962-34-8Prost-13-en-1-oic acid,9,11,15-trihydroxy-6-oxo-, (9α,11α,13E,15S)-
- 589-65-1Mercury succinate
- 58965-66-5Benzene,1,2,4,5-tetrabromo-3,6-bis(2,3,4,5,6-pentabromophenoxy)-
- 589-66-22-Butenoic acid,2-methylpropyl ester
- 58966-24-8Benzene,2-(chloromethyl)-1-methyl-4-nitro-
- 58966-93-11H-1,4,7-Triazonine,octahydro-,hydrochloride (1:3)
Hot Products
- 58969-01-0FUCHSIN BASIC
- 58-97-9UMP
- 58985-18-5Dihydroterpinyl acetate
- 58998-75-757986-28-4
- 590-02-3Butyl 2-chloroacetate
- 59004-96-5ALPHA-ENDORPHIN
- 5900-59-42-amino-4-chlorobenzamide
- 590-16-91-Bromo-2-iodoethane
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
|
Basic Information |
|
Post buying leads |
|
Suppliers |
|
Cas Database |
| Name |
Idarubicin |
EINECS | 1806241-263-5 |
| CAS No. | 58957-92-9 | Density | 1.565 g/cm3 |
| PSA | 176.61000 | LogP | 1.72060 |
| Solubility | N/A | Melting Point |
N/A |
| Formula | C26H27NO9 | Boiling Point | 725.435 °C at 760 mmHg |
| Molecular Weight | 497.502 | Flash Point | 392.529 °C |
| Transport Information | UN 2811 6.1/PG 2 | Appearance | N/A |
| Safety | 53-45 | Risk Codes | 60-61-28-40 |
| Molecular Structure |
|
Hazard Symbols |
 T+
|
| Synonyms |
5,12-Naphthacenedione,9-acetyl-7-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-,(7S-cis)-;1-Demethoxydaunorubicin;4-DMD;4-Demethoxydaunomycin;4-Demethoxydaunorubicin;Demethoxydaunorubicin; |
Article Data | 8 |
Idarubicin Chemical Properties
IUPAC Name: Idarubicin
The MF of Idarubicin (58957-92-9) is C26H28ClNO9.
The MW of Idarubicin (58957-92-9) is 533.95.
Synonyms of Idarubicin (58957-92-9): 11-Trihydroxy-(7s-cis)-alpha-l-lyxo-hexopyranosyl)oxy)- ; 4-Demethoxy-daunomyci ; 4-Demethoxy-daunorubicin ; 7,8,9,10-Tetrahydro-9-acetyl-7-((3-amino-2,3,6-trideoxy-12-naphthacenedione ; Nsc-256439;(7s-cis)-9-acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
Product Categories: Active Pharmaceutical Ingredients
Index of Refraction: 1.705
Density: 1.56 g/ml
Flash Point: 392.5 °C
Boiling Point: 725.4 °C
Storage temp: 2-8 °C
Form: solid
Idarubicin Uses
Idarubicin (58957-92-9) is used for acute myelogenous leukemia, inhibit tumor growth, anti-breast cancer.
Idarubicin Toxicity Data With Reference
| 1. | mmo-sat 2 µg/plate | ENMUDM Environmental Mutagenesis. 7 (1985),129. | ||
| 2. | dns-rat:lvr 2 mg/L | CNREA8 Cancer Research. 44 (1984),5599. | ||
| 3. | dnd-mus:fbr 1800 nmol/L | CNREA8 Cancer Research. 37 (1977),4523. | ||
| 4. | dnd-mam:lym 200 nmol/L | BBRCA9 Biochemical and Biophysical Research Communications. 69 (1976),744. | ||
| 5. | orl-mus LD50:16 mg/kg | CTRRDO Cancer Treatment Reports. 61 (1977),893. | ||
| 6. | ipr-mus LD50:3 mg/kg | CNREA8 Cancer Research. 48 (1988),926. | ||
| 7. | ivn-mus LD50:4 mg/kg | CTRRDO Cancer Treatment Reports. 61 (1977),893. |
Idarubicin Safety Profile
Poison by ingestion, intraperitoneal, and intravenous routes. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx. See also DAUNOMYCIN.
Safety information of Idarubicin (58957-92-9):
Hazard Codes .gif){kind=small}
T+
Risk Statements
60 May impair fertility
61 May cause harm to the unborn child
28 Very Toxic if swallowed
40 Limited evidence of a carcinogenic effect
Safety Statements
53 Avoid exposure - obtain special instruction before use
45 In case of accident or if you feel unwell, seek medical advice immediately (show label where possible)
RIDADR UN 2811 6.1/PG 2
WGK Germany 3
RTECS HB7877000
What can I do for you?
Get Best Price
